| Autor: |
Kenyon BM; Department of Surgery, Children's Hospital, Harvard Medical School, Boston, MA 02115, USA., Browne F, D'Amato RJ |
| Jazyk: |
angličtina |
| Zdroj: |
Experimental eye research [Exp Eye Res] 1997 Jun; Vol. 64 (6), pp. 971-8. |
| DOI: |
10.1006/exer.1997.0292 |
| Abstrakt: |
Thalidomide, when administered orally, is an inhibitor of angiogenesis in the basic fibroblast growth factor (bFGF)-induced rabbit cornea micropocket assay. We now show in the mouse that thalidomide given intraperitoneally but not orally significantly inhibits bFGF-induced and vascular endothelial growth factor (VEGF)-induced corneal neovascularization. We further demonstrate that this inhibition is independent from thalidomide's ability to suppress tumor necrosis factor-alpha (TNF-alpha) production. Experiments examining thalidomide's enantiomers reveal-that the S(-)-enantiomer has the strongest antiangiogenic activity in VEGF-induced and bFGF-induced corneal neovascularization. Structure activity studies suggest that thalidomide's anti-angiogenic activity is related to the open ring metabolites resulting from hydrolysis. Together these data support a correlation between thalidomide's antiangiogenic and teratogenic activities. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect